The Stanford Eye Chip Helping Blind Patients Read Again
A Chip the Size of a Pinhead, Restoring Sight
The device is called PRIMA, and it measures just 2 millimeters by 2 millimeters, roughly the size of a pinhead, and about half the thickness of a human hair.
It was invented by Daniel Palanker, a professor of ophthalmology at Stanford University, and is now being developed and commercialized by the California-based neural engineering company Science Corporation.
In a clinical trial published in the New England Journal of Medicine, 27 of 32 participants who completed a full year with the implant regained the ability to read letters, numbers, and words.
Twenty-six of those participants also showed a clinically meaningful improvement of at least two lines on a standard eye chart, a threshold ophthalmologists consider a genuine functional gain rather than a marginal one.
The Disease This Implant Targets
PRIMA is designed for people with geographic atrophy, an advanced and irreversible stage of dry age-related macular degeneration, or AMD.
AMD itself is the leading cause of irreversible vision loss in older adults and was projected to affect close to 196 million people worldwide.
Geographic atrophy specifically, where photoreceptor cells in the macula die off entirely, affects an estimated 5 to 8 million people globally and accounts for roughly one-fifth of legal blindness cases in North America.
There is currently no cure for AMD. The condition destroys the macula, the part of the retina responsible for sharp, detailed, central vision needed for reading, driving, and recognizing faces.
In the United States alone, advanced AMD affects an estimated 1.49 percent of adults over 40, translating to roughly one million people living with this specific form of vision loss.
Why This Form of Blindness Was Considered Untreatable
Once photoreceptor cells in the macula die, they do not regenerate, which is why geographic atrophy has long been considered a permanent, one-way loss of central vision, unlike some other causes of blindness.
How the PRIMA System Actually Works
PRIMA does not attempt to repair the dead photoreceptor cells. Instead, it bypasses them entirely using a combination of a subretinal chip and a pair of specialized augmented reality glasses.
A small camera mounted on the glasses captures the scene in front of the patient and converts it into patterns of near-infrared light.
That infrared light is projected onto the implanted chip, which behaves like a miniature solar panel, converting the light into electrical signals that stimulate the surviving neurons deeper in the retina.
As Palanker has described it, every pixel on the chip functions as its own tiny solar cell, directly translating light into the electrical signal the brain can interpret as vision.
A zoom function built into the glasses lets patients magnify text, effectively giving them a built-in visual aid alongside the restored central vision itself.
The Implant
A 2mm by 2mm wireless photovoltaic chip surgically placed beneath the macula in a roughly two-hour procedure.
The Glasses
Augmented reality glasses with a built-in camera that convert real-world images into infrared light signals sent to the chip.
The Training
Patients undergo several months of training after activation to learn to interpret the new visual patterns as letters and shapes.
Inside the Clinical Trial Results
The trial enrolled 38 patients with geographic atrophy in both eyes across five European countries, all confirmed through advanced retinal imaging before surgery.
Of the 32 patients who completed a full year in the study, 27 regained functional reading ability using the paired glasses, and safety data showed the implant could be placed under the atrophic macula without unmanageable risk.
Serious adverse events occurred mainly within the first two months after implantation, and roughly 95 percent of those events resolved within that same early window.
Based on these results, an independent Data Safety Monitoring Board recommended the device for European market approval, concluding that the benefit to patients outweighed the surgical risk.
Where Regulatory Approval Stands Today
Science Corporation has submitted a CE Mark application in Europe and expects a possible European market launch this year, while a parallel FDA approval process is now underway in the United States, building on the Breakthrough Device designation PRIMA received in 2023.
Our earlier reporting on how medical device makers are racing through regulatory pathways for non-invasive health technology highlights a similar pattern, where breakthrough designations are increasingly shaping how fast genuinely novel devices reach patients.
What Comes Next for the Technology
The current version of PRIMA uses 400 pixels, enough to restore functional reading but not full visual sharpness.
Palanker's team is now developing a higher-resolution successor with 10,000 pixels, already tested successfully in animal models, with human trials of the upgraded chip being planned.
Combined with the zoom capability already built into the glasses, Palanker has suggested that resolution increase could theoretically allow some patients to approach 20/20 visual acuity, a dramatic leap from simply recovering the ability to read.
Researchers are also exploring whether the same underlying approach could eventually extend to other forms of retinal degeneration beyond geographic atrophy specifically.
Why This Matters Beyond One Trial
For patients, the significance goes beyond a statistic. Reading again means independence: managing medications, reading a menu, recognizing a loved one's face across a room.
For the broader field of neural engineering, PRIMA is one of the clearest demonstrations yet that a brain-computer interface can restore a lost human sense, not simply monitor or assist an existing one.
That places it alongside a growing wave of neurotechnology breakthroughs reshaping what medicine considers permanent, a theme also visible in recent research into lab-grown neural tissue built from living human neurons.
For a disease with no cure and, until recently, no meaningful treatment for its most advanced stage, a device the size of a pinhead is now offering something that seemed foreclosed only a few years ago: the ability to read a printed word again.
0 Comments